Temporal Trends in Perceptions of Anti-tumor Necrosis Factor Risks and Benefits in an Online Community of Patients With Crohn's Disease.

BACKGROUND AND AIMS

Anti-tumor necrosis factor agents (anti-TNFs) have become one of the primary medical therapies for Crohn's disease (CD). We analyzed perceptions of infliximab and adalimumab in a large online community to better understand the information patients receive.

METHODS

Reddit, a vast online community, has several inflammatory bowel disease communities, the largest being /r/CrohnsDisease (rCD), with over 41,000 members. To better understand patient perceptions of biologics, we searched rCD for posts related to "infliximab," "adalimumab," and their relevant trade names. The top 20 yearly posts were extracted from 2011 to 2015 and 2011 to 2017, respectively. Manifest coding was performed. Codes were reassessed every 20 posts, resulting in 6 main sentiments. Total codes and per-comment codes were calculated for each sentiment. Percentages for each category were calculated by dividing by the total number of coded sentiments that year. Trends in rates of each sentiment were assessed using Spearman's correlation coefficients.

RESULTS

4486 comments were analyzed, and 4684 sentiments met our criteria. Negative sentiments decreased for both anti-TNFs over time (infliximab: rho = -0.90,  = .04, adalimumab: rho = -0.79,  = .04). In our primary analysis, adalimumab injection-related posts increased from 2012 to 2017 (rho = 0.83,  = .04). Positive sentiments and sentiments regarding drug costs, loss of efficacy, and diet remained stable. For infliximab and adalimumab, comment volume increased significantly over time (rho 0.90;  = .04, rho 0.89,  = .01).

CONCLUSION

Our analysis of a large online community suggests a growing acceptance of biologic therapies among patients with CD over time. These data provide additional insight into the multifaceted framework shaping patients' perceptions of anti-TNFs.